Le Lézard
Classified in: Health, Business
Subjects: CON, PDT

HeartHero Awarded Grant Funding From The Colorado Office Of Economic Development And International Trade


DENVER, May 21, 2018 /PRNewswire/ -- The Colorado Office of Economic Development and International Trade (OEDIT) has awarded startup medical device manufacturer HeartHero a $250,000 Early Stage Capital and Retention Grant to continue developing its ultra-portable, easy-to-use automatic external defibrillator (AED). HeartHero aims to make this lifesaving technology accessible and attractive to the consumer market, while simultaneously creating a better alternative for existing business and institutional markets.

According to the American Heart Association, sudden cardiac arrest (SCA) claims more than 350,000 American lives each year. Eighty percent of those SCAs occur at home, where families do not have access to a lifesaving AED.  With chances of survival decreasing 7-10 percent with each passing minute, most people suffering an SCA do not have time for the ambulance to arrive with an AED.

"OEDIT's grant will help us get one step closer to saving millions of lives from sudden cardiac arrest," said Gary Montague, HeartHero founder and CEO. "As a medical professional who has seen too many people die from sudden cardiac arrest, I am thrilled that OEDIT believes in our product and our mission. The AED market is ripe for disruption and with the help of OEDIT, we plan to do just that."

Part of OEDIT's Advanced Industry Accelerator Programs, Early Stage Capital and Retention Grants fund companies commercializing innovative technologies to create viable products that meet a market need and will be created or manufactured in Colorado and exported globally.

About HeartHero
HeartHero is the next generation automated external defibrillator. Our team is on a mission to save lives from sudden cardiac arrest, the number one killer in the United States. By developing a portable, easy-to-use AED, we aim to make lifesaving technology accessible and affordable to all. At HeartHero, we aim to empower families to help their loved ones live longer, more fulfilling lives. For more information, visit hearthero.io.

About OEDIT's Advanced Industry Accelerator Programs 
OEDIT's Advanced Industry Accelerator Programs were created in 2013 to promote growth and sustainability in Colorado's advanced industries by driving innovation, accelerating commercialization, encouraging public-private partnerships, increasing access to early-stage capital and creating a strong infrastructure that increases the state's capacity to be globally competitive. AIA encompasses three distinct grant programs: Proof of Concept, Early Stage Capital and Retention, and Commercialization Infrastructure. For more information, visit choosecolorado.com.

Media Contact:
Karen Einisman, KeetonPR
[email protected]
612-384-3763

 

SOURCE HeartHero


These press releases may also interest you

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...



News published on and distributed by: